SUPPLEMENT APPROVAL

Pfizer Inc.
U.S. Agent for Pfizer Ireland Pharmaceuticals, an Irish partnership
Attention: Marcio de Godoy, MBA, PharmD, PhD
Senior Manager, Worldwide Safety and Regulatory
500 Arcola Rd, G4347
Collegeville, PA 19426

Dear Dr. de Godoy:

Please refer to your Supplemental New Drug Application (sNDA) and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lipitor (atorvastatin calcium) tablets; 10 mg, 20 mg, 40 mg, 80 mg for the following Prior Approval and Changes Being Effected supplements.

We also refer to our approval letter dated June 23, 2017 which contained the following error: the package insert only contained the update related to the Changes Being Effected supplement (S-069) and not the pediatric updates from Prior Approval supplement (S-067).

This replacement approval letter incorporates the correction of the error. The effective approval date will remain June 23, 2017, the date of the original approval letter.

Supplement 067
This “Prior Approval” sNDA, dated and received August 26, 2016, provides for revisions of the prescribing information (PI) to include results of the following studies:

- **Study A2581172**: An 8-Week, Open-Label, Phase I Study to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Atorvastatin in Children and Adolescents with Heterozygous Familial Hypercholesterolemia.

- **Study A2581173**: A Three Year, Prospective, Open-Label Study to Evaluate Clinical Efficacy, Safety and Tolerability of Atorvastatin in Children and Adolescents with Heterozygous Familial Hypercholesterolemia.

Supplement 069
We also refer to our letter dated March 29, 2017, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for HMG-CoA reductase inhibitors. This information pertains to the risk of interstitial lung disease.
This supplemental new drug application provides for revisions to the labeling for Lipitor, consistent with our March 29, 2017, letter.

**APPROVAL & LABELING**

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**WAIVER OF HIGHLIGHTS SECTION**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).
REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to these applications, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, call Martin White, M.S., Regulatory Project Manager, at (240) 402-6018.

Sincerely,

{See appended electronic signature page}

James P. Smith, M.D., M.S.
Deputy Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JEAN-MARC P GUETTIER
06/23/2017